FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
ACN Newswire
*TOKYO and CAMBRIDGE, Mass., June 10, 2024 - (JCN Newswire) - *Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S...